{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-310286","form_type":"8-K","ticker":"INO","cik":"0001055726","company_name":"INOVIO PHARMACEUTICALS, INC.","filed_at":"2021-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.296202+00:00","generated_at":"2026-06-28T16:31:45.660548+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inovio's COVID-19 vaccine INO-4800 selected for WHO Solidarity Trial Vaccines Phase 3","bullets":["WHO confirmed Oct 26, 2021 that INO-4800 is one of two vaccines in large international Phase 3 Solidarity Trial.","Selected by independent advisory group from ~20 candidate vaccines; two more vaccines may enter later.","Trial recruiting volunteers at over 40 sites across Colombia, Mali, and the Philippines.","Inovio also conducting separate global Phase 3 INNOVATE trial with partner Advaccine."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-310286","json":"https://secwatch.observer/filing/0001193125-21-310286.json","markdown":"https://secwatch.observer/filing/0001193125-21-310286.md","text":"https://secwatch.observer/filing/0001193125-21-310286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/0001193125-21-310286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1055726/000119312521310286/d235597d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T16:31:45.660548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}